Q1 Revenue, Net Income Plummet, Cash Drains; Debt Refinancing Extends Maturity to 2031

summarizeSummary

biote Corp. reported a sharp decline in Q1 2026 revenue, net income, and Adjusted EBITDA, alongside a significant drop in cash reserves. The company also refinanced its $175 million credit facility, extending the term loan maturity to 2031, and completed an $18.5 million share repurchase liability payment.

check_boxKey Events

• Q1 2026 Financial Performance

  Total revenue decreased 8.3% to $44.9 million, net income plummeted 83% to $2.7 million, and Adjusted EBITDA fell 37% to $8.7 million compared to Q1 2025.

• Cash Position Deterioration

  Cash and cash equivalents significantly decreased from $24.1 million at December 31, 2025, to $5.3 million at March 31, 2026.

• Debt Refinancing Completed

  On May 8, 2026, the company entered into an amended and restated $175.0 million credit agreement, extending the Term Loan A maturity from May 2027 to May 2031. This refinancing replaces the existing credit facility.

• Share Repurchase & Liability Settlement

  The company repurchased 726,388 Class A common shares for $1.1 million and fully satisfied an $18.5 million share repurchase liability for Class V voting stock during Q1 2026.

auto_awesomeAnalysis

This filing reveals a company under significant financial strain, with substantial declines in profitability and a sharp reduction in cash reserves. The refinancing of the $175 million credit facility, while crucial for extending debt maturity, highlights the company's reliance on external financing amidst operational challenges. The ongoing material weakness in internal controls and the financial impact of the product recall further compound the negative outlook. Investors should be concerned about the company's ability to reverse these negative trends and improve its liquidity position.